VIDEO: Alphyn's AB-101a shows ‘market-leading’ results in atopic dermatitis

SAN DIEGO — In this Healio video perspective from the American Academy of Dermatology Annual Meeting, Alphyn Biologics CEO Neal Koller discusses new data from the company’s phase 2a trial of AB-101a for the treatment of atopic dermatitis.

“The results of this trial are market-leading for the key problems of itch, quality of life and safety,” Koller told Healio.

AB-101a (zabalafin hydrogel) is a novel, first-in-class, multi-target therapeutic natural drug. It treats both the inflammation component and bacterial component of atopic dermatitis, according to Koller.

“The bacterial component has two pieces: infected atopic dermatitis skin, which you have to treat and clear before you can clear the atopic dermatitis itself, and staph bacteria-driven atopic dermatitis flare,” he said. “In both cases, we knocked out the infection in atopic dermatitis skin and demonstrated control of the atopic dermatitis flares through the entire trial.”